Twist Bioscience (NASDAQ:TWST) Insider Sells $28,075.68 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 402 shares of Twist Bioscience stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $69.84, for a total value of $28,075.68. Following the sale, the insider directly owned 119,692 shares in the company, valued at approximately $8,359,289.28. This trade represents a 0.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Stock Performance

TWST opened at $76.17 on Friday. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $80.50. The stock has a market cap of $4.74 billion, a PE ratio of -57.27 and a beta of 2.23. The business’s 50 day moving average is $59.67 and its 200-day moving average is $47.45. The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). The firm had revenue of $110.72 million during the quarter, compared to analyst estimates of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.66) earnings per share. On average, analysts predict that Twist Bioscience Corporation will post -1.99 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Guggenheim upped their target price on Twist Bioscience from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Barclays upped their target price on Twist Bioscience from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Leerink Partners set a $80.00 target price on Twist Bioscience in a research report on Friday, May 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Friday, March 27th. Finally, Piper Sandler assumed coverage on Twist Bioscience in a research report on Thursday. They issued an “overweight” rating and a $85.00 target price for the company. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.38.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Quarry LP bought a new position in shares of Twist Bioscience in the third quarter valued at $28,000. Smartleaf Asset Management LLC increased its holdings in shares of Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after buying an additional 442 shares in the last quarter. Western Wealth Management LLC bought a new position in shares of Twist Bioscience in the first quarter valued at $31,000. Strs Ohio bought a new position in shares of Twist Bioscience in the first quarter valued at $33,000. Finally, Strategic Advocates LLC increased its holdings in shares of Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after buying an additional 906 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.